

#2/9/01 6/11/01

SHEET 1 OF 6


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. unknown 09/756,411
	APPLICANT Lori et al.	
	FILING DATE herewith	GROUP Art Unit 1623

U.S. PTO
09/756411
01/08/01

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
**	1	4,708,818	11/24/87	Montagnier et al.			
**	2	5,026,687	06/25/91	Yarchean et al.			
**	3	5,110,600	05/05/92	Green			
**	4	5,300,050	04/05/94	Rubinstein et al.			
**	5	6,046,175	04/04/00	Lori et al.			
**	6	6,093,702	07/25/00	Malley et al.			
**	7	5,521,161	05/28/06	Malley et al.			
**	8	5,736,526	04/07/98	Malley et al.			
**	9	5,736,527	04/07/99	Malley et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
**	10	EP 0 206 497	12/30/86	EPO				
**	11	WO 87/01284	03/12/87	WIPO				
me	12	WO 92/08699	05/29/92	WIPO				
me	13	WO 93/12782	07/08/93	WIPO				
me	14	WO 93/23368	11/25/93	WIPO				
me	15	WO 94/27590	12/08/94	WIPO				
me	16	WO 95/17899	07/06/95	WIPO				

** Duplicate of reference already of record on a PTO-892.

EXAMINER  L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. unknown 09/756,411
	APPLICANT Lori et al.	
	FILING DATE herewith	GROUP Art Unit 1623 unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Jre	17 ! Albert et al., <i>Experimental Cell Research</i> , 179: 417-428, 1988, "Deoxyadenosine Toxicity and Cell Cycle Arrest in Hydroxyurea-Resistant S49 T-Lymphoma Cells."
Jre	18 Altman, L.K., <i>New York Times</i> , p. 38, Sunday, September 17, 1995, "Study Challenges AZT Role as the Chief Drug for H.I.V."
Jre	19 ! Balzarini et al., <i>Molecular Pharmacology</i> , 32: 798-806, 1987, "2', 3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis."
**	20 Barre-Sinoussi et al., <i>Science</i>, 220: 868-871, 1983, "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)."
Jre	21 ! Biron et al., <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 10(1): 36-40, 1995, "Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals."
**	22 Bukrinsky et al., <i>Science</i>, 254: 233-237, 1991, "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection."
**	23 Busse et al., <i>AIDS Res. Human Retroviruses</i>, 6(9): 1139-1146, 1990, "Cellular Pharmacology and Anti-HIV Activity of 2', 3'-Dideoxyguanosine."
**	24 Centers for Disease Control, <i>Morbidity Mortality Weekly Report</i>, 30(25): 305-308, July 3, 1981, "Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men."
**	25 Chew et al., <i>Nature</i>, 361: 650-654, 1993, "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy."
Jre	26 ! Coffin, H., <i>Fundamental Virology 2nd Edition</i> , pp. 545-708, Raven Press, New York, 1991, "Retroviridae and Their Replication."
**	27 Fauci, <i>Science</i>, 239: 617-622, 1988, "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis."
**	28 Fauci, <i>Science</i>, 262: 1011-1018, 1993, "Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy."
**	29 Feorino et al., <i>Antiviral Chemistry & Chemotherapy</i>, 4(1): 55-63, 1993, "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells."
Jre	30 ! Fischl, <i>AIDS Clin. Rev.</i> , 94: 167-187, 1993, "Treatment of HIV Disease in 1993/1994."

** Duplicate of reference already cited on a PTO-892.
 ! Month of publication data is unavailable for this reference.

EXAMINER <i>L. E. Crane</i> L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. unknown 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
**	31 Fox et al., J. Infectious Diseases, 164: 1051-1057, 1991, "Lymphoid Germinal Centers are Reservoirs of Human Immunodeficiency."
me	32 Gao, <i>Aids Research and Human Viruses</i> , 10(1): Supp. 3, Abstract No. 355, 1994, ! "Mechanisms of the Enhanced Anti-HIV-1 Activities of 2', 3'-Dideoxynucleoside Analogs by Hydroxyurea."
me	33 Gao et al., <i>Clinical Research</i> , 42(2): 280A, 1994, ! "Anti-HIV-1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
me	34 Gao et al., <i>Mol. Pharmacol.</i> , 46(4): 767-772, 1994, ! "Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
**	35 Gao et al., Proc. Natl. Acad. Sci. USA, 90: 8925-8928, October 1993, "Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication."
me	36 Goulaouic et al., <i>C.R. Acad. Sci. Paris</i> , 317: 430-436, 1994, ! "Potentiation of 2', 3'-Dideoxycytidine (ddc) by Hydroxyurea and Thymidine on the Moloney Murine Leukemia Virus (MoMLV) Early Replicative Steps."
me	37 Goulaouic et al., <i>Virology</i> , 200: 87-97, 1994, ! "Exogenous Nucleosides Promote the Completion of MoMLV DNA Synthesis in GO-Arrested Balb c/3T3 Fibroblasts."
me	38 Hao et al., <i>Molecular Pharmacology</i> , 34:431-435, 1988, ! "Factors Determining the Activity of 2', 3'-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus In Vitro."
**	39 Hirsch et al., N. Engl. J. Medicine, 328(23): 1686-1695, 1993, "Therapy for Human Immunodeficiency Virus Infection."
me	40 Huber et al., <i>J. of Biological Chemistry</i> , 264(8): 4669-4678, 1989, ! "Human Immunodeficiency Virus I Reverse Transcriptase."
me	41 Hubscher, H., <i>Experientia</i> , 39(1): 1-25, 1983, ! "DNA Polymerases in Prokaryotes and Eukaryotes: Mode of Action and Biological Implications."
me	42 Ji et al., <i>Mol. Gen. Genet.</i> , 226: 257-264, 1991, ! "Analysis of Mutagenesis Induced by a Thermolabile T4 Phage Deoxycytidylate Hydroxymethylase Suggests Localized Deoxyribonucleotide Pool Imbalance."
**	43 Karlsson et al., Eur. J. Biochem, 186: 689-694, 1989, "Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells."
me	44 Kati et al., <i>J. of Biological Chemistry</i> , 267(36): 25988-25997, 1992, ! "Mechanism and Fidelity of HIV Reverse Transcriptase."

** Duplicate of reference already of record on a PTO-892.

EXAMINER <i>me</i> L. E. Crane	DATE CONSIDERED 06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

! Month of publication data is unavailable for this reference.

COPY FOR [] File [] Applicant

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. —unknown— 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 —unknown—

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
Jre	45	Langreth, <i>The Wall Street Journal</i> , p. B12, November 21, 1995, "FDA Gives Approval to Glaxo, Sequus to Market Separate AIDS Therapies."
	46	Licastro et al., <i>Biochem. Biophys. Res. Comm.</i>, 132(3): 929-933, 1985, "Inhibition of Polymerases- α and - β Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells."
Jre	47	Lien, <i>Progress in Drug Research</i> , 31: 101-126, 1987, "Ribonucleotide reductase inhibitors as anticancer and antiviral agents."
	48	Lori et al., <i>Antiviral Res.</i> , Vol. 23, Supp. 1, page 63, 1994, "Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1."
Jre	49	Lori et al., <i>J. of Virol.</i> , 66(8): 5067-5074, 1992, "Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions."
	50	Lori et al., <i>International Conference on Aids</i> , 10(1): 8, Abstract No. 007b, 1994 "Hydroxyurea as a Novel Potent Inhibitor of HIV-1 Replication."
Jre	51	Lori et al., <i>Science</i>, 266(5186): 801-805, 1994, "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus Type 1 Replication."
	52	Malley et al., <i>The Lancet</i> , 343(8908): 1292, 1994, "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds."
Jre	53	Malley, <i>Proc. Nat. Acad. Sci. USA</i> , 91(23): 11017-11021, November 1994, "Synergistic Anti-Human Immunodeficiency Virus Type 1 Effect of Hydroxamate Compounds with 2', 3'-Dideoxyinosine in Infected Resting Human Lymphocytes."
	54	Marquez et al., <i>J. Med. Chem.</i>, 33(3): 978-985, 1990, "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV."
Jre	55	Matsumoto et al., <i>The Journal of Immunology</i> , 131(6): 2762-2766, 1983, "Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycytosine in Resting Lymphocytes."
	56	McCune et al., <i>Cell</i> , 53: 55-67, 1988, "Endoproteolytic Cleavage of gp160 is Required for the Activation of Human Immunodeficiency Virus."
Jre	57	Medina et al., <i>Antimicrobial Agents and Chemotherapy</i> , 36(5): 1127-1130, 1992, "Ganciclovir Antagonizes the Anti-Human-Immunodeficiency Virus Type I Activity of Zidovudine and Didanosine In Vitro."
	58	Meyerhans et al., <i>Journal of Virology</i> , 68(1): 535-540, 1994, "Restriction and Enhancement of Human Immunodeficiency Virus Type 1 Replication by Modulation of Intracellular Deoxynucleosides Triphosphate Pools."

EXAMINER

J E Crane

L. E. Crane

DATE CONSIDERED

06/12/01

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. UNKNOWN 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 UNKNOWN

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
<i>Me</i>	59	Meyerhans et al., <i>VIII International Conference on AIDS/III STD World Congress</i> , 2: A22-2118, July 1992, "The Intracellular Nucleotide Pool Effects HIV Replication."
<i>Me</i>	60	New York Times, p. B19, November 24, 1995, "Study Puts Risk of H.I.V. in Young U.S. Men at 1 in 92."
**	61	Pauwels et al., J. Virological Methods, 20: 309-321, 1988, "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds."
<i>Me</i>	62	Pegoraro et al., <i>Experimental Cell Res.</i> , 68: 283-290, 1971, "Thymidine Kinase, Deoxycytidine Kinase and Deoxycytidylate Deaminase Activities in Phytohaemagglutinin Stimulated Human Lymphocytes."
<i>Me</i>	63	Perno et al., <i>J. of Exp. Medicine</i> , 168: 1111-1125, 1988, "Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-III _g a-L) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2', 3'-Dideoxynucleosides."
<i>Me</i>	64	Popovic et al., <i>Science</i> , 224: 467-500, 1984, "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-Aids."
<i>Me</i>	65	Robinson, W., <i>Fundamental Virology 2nd Edition</i> , pp. 989-1021, Raven Press, New York, 1991, "Hepadnaviridae and Their Replication."
**	66	Root-Bernstein, R.S., Genetic Engineering News, pp. 4-6, September 1, 1992, "AIDS is More than HIV: Part I."
**	67	Root-Bernstein, R.S., Genetic Engineering News, pp. 4-5, September 15, 1992, "AIDS is More than HIV: Part II."
<i>Me</i>	68	Safrin et al., <i>Journal of Medical Virology</i> , Supplement 1, pp. 146-149, 1993, "Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection."
**	69	Schnittman et al., Science, 245: 305-308, 1989, "The Reservoir for HIV-1 in Human Peripheral Blood is a T Cell that Maintains Expression of CD4."
**	70	Schoofs, New York Times Magazine, pp. 32-35, June 21, 1998, "The Berlin Patient."
**	71	Sigma Chemical Company, catalog, St. Louis, MO, pp. 321 and 341-342, 1992, "Biochemicals/Organic Compounds for Research and Diagnostic Reagents."
<i>Me</i>	72	Simonelli et al., <i>European Aids Clinical Society, Book of Abstracts</i> , September 1995, "Hydroxyurea as an Antiretroviral Drug in HIV Infected Patients: Clinical, Immunological and Virological Evaluation."

EXAMINER	<i>L. E. Crane</i> L. E. Crane	DATE CONSIDERED	06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH061.1CP1C2	APPLICATION NO. --- unknown --- 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Lori et al.	
		FILING DATE herewith	GROUP Art Unit 1623 --- unknown ---

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
***	73 Snyder et al., DNA Repair and Its Inhibition Nucleic Acids Symposium Series No. 13, Collins et al., eds., Chapter 2, pp. 13-33, IRL Press, Oxford, England, 1984,
	"The Accumulation of DNA Breaks Due to Incision: Comparative Studies with Various Inhibitors."
**	74 Snyder et al., Mol. Pharmacol., 28(6): 574-580, 1985,
	"Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts."
<i>Pre</i>	75 Stevenson et al., <i>The EMBO Journal</i> , 9(5): 1551-1560, 1990,
	! "HIV-1 Replication is Controlled at the Level of T Cell Activation and Proviral Integration."
<i>Pre</i>	76 T'Ang et al., <i>J. Med. Chem.</i> , 28: 1103-1106, 1985,
	! "Optimization of the Schiff Bases of N-Hydroxy-N' aminoguanidine as Anticancer and Antiviral Agents."
<i>Pre</i>	77 Trono, D., <i>J. of Virol.</i> , 66(8): 4893-4900, 1992,
	! "Partial Reverse Transcripts in Virions from Human Immunodeficiency and Murine Leukemia Viruses."
<i>Pre</i>	78 Varmus et al., <i>RNA Tumor Viruses, Molecular Biology of Tumor Viruses 2nd Ed.</i> , Chapter 5, pp. 369-512, 1982,
	! "Replication of Retroviruses."
<i>Pre</i>	79 Vila et al., <i>Lancet</i> , 348(9021): 203-204, July 20, 1996,
	"1-year follow-up of the use of hydroxycarbamide and didanosine in HIV Infection."
***	80 Vila et al., The Lancet, 350(9078): 635-636, August 30, 1997,
	"Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]."
<i>Pre</i>	81 Villani, et al, "Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I, <i>Journal of Clinical Pharmacology</i> , 36, 117-121 (1996)
<i>Pre</i>	82 Wilson et al. <i>J. Clin. Invest.</i> , 64: 1475-1484, 1979,
	! "Purinogenic Immunodeficiency Disease - Differential Effects of Deoxyadenosine and Deoxyguanosine on DNA Synthesis in Human T Lymphoblasts."
***	83 Yarchean et al., N. Engl. J. Medicine, 321(11): 726-738, 1989,
	"Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides."
***	84 Zack et al., Cell, 61: 213-222, 1990,
	"HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure."

** Duplicate of reference already of record on a PTO-892.

! Month of publication data is unavailable for this reference.

O:\DOCS\N\W\N\WV-3882.DOC
010501

EXAMINER	L. E. Crane <i>LEC</i>	DATE CONSIDERED	06/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

COPY FOR [] File [] Applicant